After delivering more than 22 million healthy starts, Baebies—like all babies do—has grown. What began with a focus on newborn screening has now expanded to cover diagnostics for all ages, recognizing that our technology is just as impactful for adults as it is for infants.

Our mission has evolved from “everyone deserves a healthy start” to everyone deserves to be healthy, where any test can be taken anywhere, for everyone.

A Strategic Licensing Path for Newborn Screening

As part of our broader vision, Baebies has licensed and transferred its newborn screening business to a strategic partner. This ensures that newborn screening customers remain well-supported while unlocking resources for Baebies to accelerate innovation in multifunctional diagnostics.

Vamsee Pamula, Ph.D., Co-Founder and President of Baebies, explains:
“After delivering 22 million healthy starts, we realized that our digital microfluidics technology has the potential to serve all patients—not just newborns. Our vision has expanded because the underlying digital microfluidics is equally applicable across all age groups. By broadening our scope, we unlock its full potential to provide rapid, accessible testing for anyone, anywhere. Our mission now is clear: everyone deserves to be healthy, where any test can be taken anywhere, for everyone.”

Richard West, Co-Founder and CEO of Baebies, adds:
“Licensing our newborn screening solutions to our strategic partner allows us to ensure the full potential of newborn screening is realized while enabling Baebies to focus on advancing cost-effective, multifunctional point of care testing solutions for newborns, pediatrics, and adults alike. Our technology is designed to make diagnostics more accessible, ensuring that patients across all age ranges benefit from fast, reliable, and comprehensive testing.”

Expanding Access to Multifunctional Testing

Baebies pioneered multifunctional testing, opening new possibilities in rapid, versatile, and accessible diagnostics. Powered by our proprietary digital microfluidics technology, Baebies’ approach integrates molecular, immunoassay, chemistry, and coagulation testing on a single, compact platform – eliminating the need for separate instruments. At the heart of our work is FINDER®, the only multifunctional diagnostic platform demonstrating capabilities across molecular, immunoassay, chemistry, and coagulation testing. This breakthrough enables fast, comprehensive results from a small-volume sample, transforming diagnostics across hospitals, clinics, pharmacies, and decentralized care settings. With its ability to deliver fast, reliable results from a single small-volume sample, FINDER is transforming diagnostics in hospitals, clinics, pharmacies, and decentralized care settings.

• FINDER G6PD chemistry test is FDA-cleared and in use across the U.S. and internationally.
• Additional tests in molecular, coagulation, and immunoassays are advancing through clinical studies, broadening FINDER’s impact on timely, comprehensive patient insights.
• Beyond FINDER, Baebies is developing a next-generation handheld platform with the same multifunctional capabilities, designed for even more distributed and accessible testing.

Our track record of turning early-stage R&D funding from organizations such as NIH, CDC, RADx, and BARDA into successful products underscores our commitment to innovation.

Recognition and Future Outlook

FINDER has already garnered significant industry acclaim, including the prestigious Disruptive Technology Award and the People’s Choice Award at the Association for Diagnostics & Laboratory Medicine (ADLM), reinforcing its role in shaping the future of diagnostics.

Baebies remains headquartered in Research Triangle Park, North Carolina, with a satellite facility in Hyderabad, India. From these hubs, we continue to make advanced testing solutions available to more people, in more places, than ever before.

We’re excited to share this update as Baebies continues to grow and expand its impact. By licensing our newborn screening business to a trusted partner, we ensure that newborn screening customers remain well-supported while we focus on advancing multifunctional diagnostics for patients of all ages. This strategic move allows us to accelerate innovation and broaden access to rapid, reliable testing, staying true to our mission:

Any Test, Anywhere, Everyone™.

Baebies is shaping a future where diagnostics are no longer bound by complexity, location, or patient age—because healthcare should work for everyone, everywhere.